Peripheral Neuropathy Incidence with Trastuzumab
Trastuzumab (Herceptin) causes peripheral neuropathy in approximately 2-11% of patients, with the majority being low-grade sensory symptoms; this is substantially lower than the neuropathy rates seen with chemotherapeutic agents like taxanes or vinca alkaloids.
Incidence Data from FDA-Approved Labeling
The FDA label for Herceptin provides the most authoritative data on neuropathy incidence:
Adjuvant Breast Cancer Treatment
- In the NCCTG N9831 trial, motor neuropathy (Grade 2-5) occurred in 12.2% of patients receiving Herceptin plus chemotherapy versus 9.1% with chemotherapy alone, and sensory neuropathy occurred at similar rates between arms 1
- The NSABP B31 trial collected only Grade 3-5 adverse events and treatment-related Grade 2 events; specific neuropathy rates were not prominently featured in the safety profile, suggesting low incidence of severe neuropathy 1
- In the HERA trial, paresthesia occurred in 2% of patients receiving Herceptin versus 0.6% in the observation arm (all grades, with <1% Grade 3 or higher) 1
Metastatic Breast Cancer Treatment
- In studies H0648g and H0649g, peripheral neuritis occurred in 2% of Herceptin monotherapy patients 1
- When combined with paclitaxel, peripheral neuritis was reported in 23% of patients receiving Herceptin plus paclitaxel versus 16% with paclitaxel alone, and neuropathy occurred in 11% versus 3%, respectively 1
- Paresthesia occurred in 9% of Herceptin monotherapy patients, 48% with Herceptin plus paclitaxel (versus 39% paclitaxel alone), and 17% with Herceptin plus anthracycline/cyclophosphamide (versus 11% with chemotherapy alone) 1
Metastatic Gastric Cancer
- In the ToGA trial, the FDA label does not list peripheral neuropathy as a significant adverse event for Herceptin in gastric cancer, suggesting minimal contribution to neuropathy in this setting 1
Clinical Context and Interpretation
The neuropathy observed with Herceptin-containing regimens is predominantly attributable to the chemotherapy backbone (particularly taxanes) rather than trastuzumab itself 1. This is evidenced by:
- The HERA trial (Herceptin monotherapy after chemotherapy completion) showed only 2% paresthesia versus 0.6% in observation, indicating minimal intrinsic neurotoxicity 1
- When Herceptin is combined with taxanes, neuropathy rates increase modestly (2-4% absolute increase) compared to taxane monotherapy, but this likely reflects additive toxicity rather than synergistic neurotoxicity 1
Comparison to Other Agents
For clinical perspective, trastuzumab's neuropathy profile is dramatically more favorable than:
- Bortezomib: 35-46% overall peripheral neuropathy incidence (13% Grade 3-4) 2, 3
- Thalidomide: 25-83% overall incidence with 15% requiring treatment discontinuation 2
- Taxanes: Baseline neuropathy rates of 39-48% when used alone 1
- Vinca alkaloids: Can cause severe neuropathy including rare cases of tetraplegia 4
Common Pitfalls
- Do not attribute neuropathy in Herceptin-containing regimens solely to trastuzumab—the chemotherapy partner (especially taxanes) is the primary driver 1
- Do not withhold or dose-reduce Herceptin for neuropathy—instead, adjust the neurotoxic chemotherapy component according to established guidelines 5, 6
- Monitor for neuropathy symptoms during combination therapy, but recognize that Herceptin monotherapy (as maintenance or in metastatic disease after chemotherapy) carries minimal neuropathy risk 1